EUCTR2006-000654-43-IT进行中（未招募）不适用
Phase 3 Multinational, Randomized, Double Blind, Placebo Controlled Study of the Effect of Daily Treatment with MPC-7869 on Measures of Cognition, Activities of Daily Living and Global Function in Subjects with Mild Dementia of the Alzheimer s Type - ND
Myriad Pharmaceuticals Inc0 个研究点目标入组 800 人开始时间: 2006年8月30日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 800
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Eligible subjects have dementia with diagnosis of probable Alzheimer s disease by the Diagnostic and Statistical Manual of Mental Disorders, version IV text revised DSM-IV TR and the NINCDS-ADRDA criteria, and Mini Mental Status Exam MMSE score between 20 and 26 inclusive; age 8805; 55. Acetylcholinesterase inhibitors are permitted if therapy was started at least 6 months prior to enrollment. Memantine is permitted if therapy with stable doses was started at least 3 months prior to enrollment. Stable doses of antipsychotics, anxiolytics, antidepressants and low dose aspirin are permitted.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
- •Eligible subjects have dementia with diagnosis of probable Alzheimer s disease by the Diagnostic and Statistical Manual of Mental Disorders, version IV text revised DSM-IV TR and the NINCDS-ADRDA criteria, and Mini Mental Status Exam MMSE score between 20 and 26 inclusive; age 8805; 55. Acetylcholinesterase inhibitors are permitted if therapy was started at least 6 months prior to enrollment. Memantine is permitted if therapy with stable doses was started at least 3 months prior to enrollment. Stable doses of antipsychotics, anxiolytics, antidepressants and low dose aspirin are permitted.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Exclusions include diagnosis of other organic neurologic conditions, uncontrolled medical conditions cardiac, renal, hepatic or metabolic , active malignancy, chronic nonsteroidal antiinflammatory drugs use, and treatment with CYP2C9 inhibitors.
- •Exclusions include diagnosis of other organic neurologic conditions, uncontrolled medical conditions cardiac, renal, hepatic or metabolic , active malignancy, chronic nonsteroidal antiinflammatory drugs use, and treatment with CYP2C9 inhibitors.
研究者
相似试验
进行中（未招募）
不适用
Phase 3 Multinational, Randomized, Double Blind, Placebo Controlled Study of the Effect of Daily Treatment with MPC-7869 on Measures of Cognition, Activities of Daily Living and Global Function in Subjects with Mild Dementia of the Alzheimer's TypeMild Dementia of the Alzheimer's TypeEUCTR2006-000654-43-GBMyriad Pharmaceuticals, Inc800
进行中（未招募）
不适用
Phase 3 Multinational, Randomized, Double Blind, Placebo Controlled Study of the Effect of Daily Treatment with MPC-7869 on Measures of Cognition, Activities of Daily Living and Global Function in Subjects with Mild Dementia of the Alzheimer's TypeMild Dementia of the Alzheimer's TypeEUCTR2006-000654-43-NLMyriad Pharmaceuticals, Inc800
进行中（未招募）
不适用
Phase 3 Multinational, Randomized, Double Blind, Placebo Controlled Study of the Effect of Daily Treatment with MPC-7869 on Measures of Cognition, Activities of Daily Living and Global Function in Subjects with Mild Dementia of the Alzheimer's TypeEUCTR2006-000654-43-BEMyriad Pharmaceuticals, Inc800
进行中（未招募）
不适用
Phase 3 Multinational, Randomized, Double Blind, Placebo Controlled Study of the Effect of Daily Treatment with MPC-7869 on Measures of Cognition, Activities of Daily Living and Global Function in Subjects with Mild Dementia of the Alzheimer's TypeEUCTR2006-000654-43-DKMyriad Pharmaceuticals, Inc800
进行中（未招募）
不适用
Phase 3 Multinational, Randomized, Double Blind, Placebo Controlled Study of the Effect of Daily Treatment with MPC-7869 on Measures of Cognition, Activities of Daily Living and Global Function in Subjects with Mild Dementia of the Alzheimer's TypeMild Dementia of the Alzheimer's TypeEUCTR2006-000654-43-DEMyriad Pharmaceuticals, Inc800